SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised outlook have been overshadowed by a steep selloff, with traders pointing to negative cash flow, heavy spending to expand capacity, rich valuation, and broader AI-trade concerns. Bulls view the drop as an overreaction to investment in growth, while bears question whether demand and earnings will translate into cash.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention as shares slide toward record lows, with traders debating whether the decline could pause for a relief bounce or continue amid concerns about dilution, weak fundamentals and Trump-linked political uncertainty. The conversation also connects the bearish mood to the Iran conflict, oil and inflation pressures, and the approaching midterms, while some traders point to earnings as a possible catalyst.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on encouraging early Phase 1 azer-cel results in progressive MS, with traders highlighting the initial safety profile and signs of disability stability or improvement. Many see it as a potential second growth driver alongside BRIUMVI, while others caution that the study is small and preliminary and note the stocks muted reaction to the data.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETRs rally is being framed by traders as a potential short squeeze, with the community citing high short interest, a small float, tight share availability and company buybacks. Some expect repurchases and turnaround updates to add pressure, while others caution that a squeeze is not confirmed and question the rallys staying power.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom is under pressure after BDR Pharmaceuticals sued the FDA over its refusal to accept a generic application referencing VOQUEZNA, challenging exclusivity that protects the drug from generic competition through 2032. Traders debate the risk: some see the lawsuit as a long-term overhang if it succeeds, while others argue the challenge is uncertain and VOQUEZNA sales can keep growing in the meantime.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is drawing attention after quarterly results beat earnings expectations and management raised its full-year EPS outlook, while revenue came in slightly below estimates and the shares sold off. Traders are debating whether the results and stronger guidance outweigh concerns about the revenue miss and a planned workforce reduction tied to restructuring and AI preparation.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention amid a steep decline and persistent weakness, with traders questioning whether its large distribution is sustainable and criticizing Icahn Enterprises losses, dilution, and capital allocation. Some investors argue the companys CVR Energy stake and other assets are undervalued and point to short interest as potential support, while skeptics expect further pressure and possible distribution cuts.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

DXYZ is drawing attention as a public-market proxy for private AI companies, especially Anthropic, with traders focused on its anticipated IPO filing and how updated valuations could affect the funds NAV. Bulls see the IPO speculation and reported NAV discount as potential support, while skeptics point to possible delays, stale valuation estimates, and weak price action.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

A sharp selloff has investors questioning Auvelitys commercial momentum, especially whether prescriptions are accelerating after its Alzheimers agitation launch and whether growth can support improving profitability. Bulls argue sample use and long-term-care channels may obscure demand in prescription data, while skeptics cite sluggish reported scripts and managements lack of clarity ahead of the Q3 results.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is drawing attention after a steep pullback from its highs and a breakdown to multi-month lows, with traders split between viewing the selling as exhausted and expecting a rebound or anticipating further downside. The discussion also reflects uncertainty about AI data-center spending and the upcoming earnings report, alongside longer-term optimism about infrastructure demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Equity

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies.</li><li>The pharma giant said the acquisition strengthens its neuroscience pipeline with two late-stage programs targeting treatment-resistant depression.</li><li>Over the past year, Compass has significantly outperformed ATAI.</li></ul>Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in cash at closing, plus up to $2.50 per share tied to future development and regulatory milestones for ATAI's two lead programs, bringing total potential value to as much as $9.25 per share.&nbsp;Based on ATAI's Wednesday close of around $5.36, the $6.75 per share cash offer represents a premium of approximately 25.9%. Taking total potential consideration of $9.25 into account, the premium to Wednesday's close would be approximately 72.6%.The deal is expected to close in the third quarter (Q3), pending shareholder and regulatory approval.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/ATAI_2026_07_16_06_37_17_png_4cad859a33.webp" alt="ATAI_2026-07-16_06-37-17.png" width="2643" height="1588"><figcaption>ATAI stock historical performance vs. pre-market on July 16. | Source: TradingView</figcaption></figure><a href="https://stocktwits.com/symbol/ATAI/">ATAI stock</a> jumped over 33% in pre-market trade, paring gains from a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-atai-stock-soaring-59-after-hours/cZZPl7dR7rk">jump of around 60%</a> earlier in the day. If pre-market grains hold, ATAI’s stock is on track to hit its highest levels since December 2021 and mark the biggest single-day jump in the company’s history.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_063534529_png_3a8bd239cd.webp" alt="koyfin_20260716_063534529.png" width="2400" height="1240"><figcaption>ATAI stock historical single-day stock price changes. | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/LLY">LLY's stock</a> was also among the top trending tickers on Stocktwits, edging higher by around 0.4% in pre-market trade.<h2 class="st-heading-2">What is Lilly Buying?</h2>ATAI's lead asset is BPL-003, an intranasal, synthetic form of 5-MeO-DMT for treatment-resistant depression that has already earned FDA Breakthrough Therapy Designation and entered Phase 3 activities, following a Phase 2b study showing rapid and durable symptom reduction after a roughly two-hour in-clinic session.&nbsp;Its second program, VLS-01, is a buccal film formulation of DMT currently in Phase 2b. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, Lilly Neuroscience's president.&nbsp;ATAI co-founder and CEO Srinivas Rao said the deal gives the company's pipeline "the resources and scale" to move faster than it could independently.<h2 class="st-heading-2">Why Is CMPS Stock Rallying Too?</h2><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> gained more than 7% in pre-market trade, and the move isn't purely coincidental. ATAI has historically been Compass's largest shareholder, though its stake has fallen from a peak of roughly 29% to 4.96% as of a February 2026 filing, dropping it below the 5% threshold requiring continued disclosure of its position.CMPS shares are also riding a separate, broader tailwind. Regulatory momentum for psychedelic therapies has been building steadily since President Donald Trump signed an executive order in April directing the Federal Drug Administration (FDA) to fast-track review of psychedelic drugs with Breakthrough Therapy designation.&nbsp;Earlier this week, the FDA announced a public hearing on psychedelic therapies and published final clinical guidance for developers on July 14. The Department of Health and Human Services (HHS) and the Department of Veterans Affairs also announced a new collaboration in anticipation of the first investigational drug approvals.&nbsp;<h2 class="st-heading-2">How Does Retail Feel About AtaiBeckley-Eli Lilly Deal?</h2>Retail sentiment around ATAI stock on Stocktwits rose to ‘extremely bullish’ from ‘bullish’ territory over the past day. Chatter stayed at ‘extremely high’ levels. Meanwhile, sentiment around CMPS stock fell to ‘neutral’ from ‘bullish’ territory, accompanied by chatter at ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_07_16_072103_png_95d0276b5f.webp" alt="Screenshot 2026-07-16 072103.png" width="1272" height="690"><figcaption>ATAI stock retail sentiment on July 16 as of 7:30 a.m. ET | Source: Stocktwits&nbsp;</figcaption></figure>Retail traders on the platform expressed excitement about what the takeover could mean for AtaiBeckley’s future growth.<stembedurl>https://www.stocktwits.com/LoadedUP1000/message/659184838</stembedurl><h2 class="st-heading-2">Comparing The Fundamentals</h2>The two companies sit at different stages of development. ATAI’s stock carries a ‘Strong Buy’ rating from two analysts, and a ‘Buy’ rating from 12 out of the 14 analysts covering the stock, according to Koyfin data. The average price target for the shares is around $14.17, and a trailing one-year return of about 102%.Wall Street was similarly bullish on Compass as well. CMPS Stock carries a ‘Strong Buy’ rating from three analysts and a ‘Buy’ rating from 12 out of the 15 analysts covering the stock. The average price target for the shares is around $24.47, implying a roughly 84% potential upside from Wednesday's close.Neither company currently generates meaningful revenue. Compass has posted essentially $0 in quarterly sales across every quarter tracked since early 2025, reflecting its status as a clinical-stage company with no approved products yet. Consensus estimates project continued losses, including a projected adjusted loss of $0.31 per share for the quarter ending June 30.&nbsp;ATAI shows a similar profile, with quarterly sales in the range of just $0 to $2 million and a projected adjusted loss of $0.11 per share for the same period.Over the past year, Compass has significantly outpaced ATAI since mid-April, gaining nearly 93% year-to-date versus ATAI's roughly 31%<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_061620094_png_c1a394bb97.webp" alt="koyfin_20260716_061620094.png" width="2400" height="1240"><figcaption>CMPS stock vs. ATAI stock performance year-to-date. | Source: Koyfin</figcaption></figure>Unlike ATAI, which will now become part of Eli Lilly, Compass remains an independent, publicly traded company focused on developing psychedelic therapies for treatment-resistant mental health conditions.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-says-53-b-offer-for-pay-pal-is-simply-too-low/cZZPR3LR7Ai">Michael Burry Says $53B Offer For PayPal Is 'Simply Too Low' – ‘The Big Short’ Investor Expects Higher Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)

Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.

AtaiBeckley Inc.

COMPASS Pathways

Lilly(Eli) & Co

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

AdvisorShares Psychedelics ETF

SPDR Pharmaceuticals ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

PILL Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Fundamentals

Latest PILL News